A Haynes and Boone, LLP deal team represented Clinigen Limited in its acquisition of Drug Safety Navigator Inc. (DSN), a specialist pharmacovigilance service provider based in the U.S.
A global pharmaceutical services company focused on providing ethical access to medicines, Clinigen said the acquisition enables it to add vital pharmacovigilance capabilities to its services offering for pharmaceutical and biotech clients.
“The acquisition of Drug Safety Navigator represents an important step in expanding our service offering to pharma and biotech companies across the globe and provides another touchpoint to engage with our clients along the medicine lifecycle,” Clinigen Chief Executive Officer David Bryant said in an announcement.
Haynes Boone Partner Simin Sun (Corporate and Mergers & Acquisitions) led the team representing Clinigen in the transaction. He was assisted by a multi-practice team that included.
Partners Randy Peak and Jennifer Kreick (Healthcare and Life Sciences)
Counsel Farr Nolen (Real Estate)
Partner Raquel Alvarenga (Labor and Employment)
Partner Suzie Trigg and Associate Tony Subketkaew (FDA Regulatory and Compliance);
Counsel Edward Lebow (Regulatory)
Haynes and Boone, LLP is an international corporate law firm with 18 offices spanning Texas, New York, California, Charlotte, Chicago, Denver, Washington, D.C., London, Mexico City and Shanghai, providing a full spectrum of legal services in energy, technology, financial services and private equity. With 600 lawyers, Haynes Boone is ranked among the largest U.S.-based firms by The National Law Journal, The American Lawyer and The Lawyer. It was recognized in the BTI Consulting Group’s 2022 “A-Team” report, which identifies the law firms that in-house counsel commend for providing superior client service.